Table 1

Demographic and baseline characteristics of the mITT population
Tigecycline (n = 268) Comparator (n = 263)
Age, years, mean (SD) 51.1 (16.11) 51.54 (16.90)
Males (%) 60.8 64.3
Ethnic origin (%)
 White 52.6 55.5
 Asian 22.4 22.1
 Black 16.4 15.2
 Hispanic 5.6 4.9
 Other 3.0 2.3
Weight, mean (SD) 87.8 (30.6) 90.4 (34.8)
Creatinine clearance, mL/min, mean (SD) 114.23 (60.73) 112.88 (59.94)
Comorbid conditions (%)
 Diabetes mellitus 31.7 32.7
 Peripheral vascular disease 14.2 11.0
 IV drug use 4.5 4.6
Prior antibiotic failure (%) 20.5 22.4
Clinical diagnosis, n (%)*
 Deep soft tissue infection 186 (69.4) 176 (66.9)
 Major abscesses 47 (17.5) 60 (22.8)
 Infected ulcers 31 (11.6) 26 (9.9)

*Includes 3 burns and 1 “other” diagnosis in tigecycline subjects and 1 burn in comparator subjects. Includes cellulitis (168 and 166 patients in the tigecycline and comparator groups, respectively), wound infections (8 and 6 patients, respectively), bites (8 and 4 patients, respectively), and IV catheter infections (2 and 0 patients, respectively). No statistically significant differences between groups. mITT, modified intent-to-treat; SD, standard deviation.

Matthews et al.

Matthews et al. BMC Infectious Diseases 2012 12:297   doi:10.1186/1471-2334-12-297

Open Data